Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 13 of 14

  1. R22044-HV-2533

    Lacuna Pharma Pty Ltd

    Heathy volunteer trial

    phase 1 other active

    1 trial

  2. R2411201

    Lacuna Pharma Pty Ltd

    Influenza

    phase 1 other active

    1 trial

  3. R2810-ONC-1787

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

    phase 1 other active

    1 trial

  4. R5054-ONC-1843

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  5. R5458-668-ALG-2219

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

  6. R5458-ONC-2012

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  7. R5459-1979-LN-2459

    Lacuna Pharma Pty Ltd

    Lupus Nephritis

    phase 1 other active

    1 trial

  8. R6569-ONC-1933

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  9. RAY104CT

    Lacuna Pharma Pty Ltd

    Nervous System disease

    phase 1 other active

    1 trial

  10. RAY902CT

    Lacuna Pharma Pty Ltd

    Bullous pemphigoid, Behçet’s Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  11. RAY903CT

    Lacuna Pharma Pty Ltd

    Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, Behçet’s Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  12. RC01T001

    Lacuna Pharma Pty Ltd

    Complement-mediated diseases

    phase 1 other active

    1 trial

  13. RDW483/0155/2

    Lacuna Pharma Pty Ltd

    Comparative bioavailability study under fasting conditions

    phase 1 other active

    1 trial

  14. RHO-11-003

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a pharmacokinetic and pharmacodynamic safety study in healthy subjects)

    phase 1 other active

    1 trial

  15. RP-L301-0119

    Lacuna Pharma Pty Ltd

    Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

    phase 1 small molecule active

    1 trial

  16. RUXOL-18-24

    Lacuna Pharma Pty Ltd

    Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host-disease.

    phase 1 other active

    1 trial

  17. Randomized for not applicable (submitted trial is bioavailability)

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is bioavailability)

    phase 1 other active

    1 trial

  18. Randomized for not applicable (submitted trial…

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  19. SNT-I-VAM-025

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

  20. SNT-I-VAM-026

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

  21. SOLOMON-I

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial

  22. SOR102-101

    Lacuna Pharma Pty Ltd

    Ulcerative colitis

    phase 1 other active

    1 trial

  23. SPI-62-CL-1002

    Lacuna Pharma Pty Ltd

    polymyalgia rheumatica

    phase 1 other active

    1 trial

  24. STA101JG

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  25. STP938-301

    Lacuna Pharma Pty Ltd

    Thrombocythaemia

    phase 1 other active

    1 trial

  26. Safety for A Phase 1, Randomized, Double-B…

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  27. TAMSU-12-24

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial

  28. TAMSU-13-24

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial

  29. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  30. TISA-818-22101

    Lacuna Pharma Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 1 other active

    1 trial

  31. TRAME-13-25

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  32. TV44749-BA-10196

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  33. TV56192-PD-10191

    Lacuna Pharma Pty Ltd

    Pruritus

    phase 1 other active

    1 trial

  34. TV56286-MB-10193

    Lacuna Pharma Pty Ltd

    Healthy participant

    phase 1 other active

    1 trial

  35. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  36. The clinical trial to study a new drug, AP-2.

    Lacuna Pharma Pty Ltd

    ALS and related disorders like frontotemporal dementia and Alexander disease.

    phase 1 other active

    1 trial

  37. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  38. UECHUP-ALM/23-6

    Lacuna Pharma Pty Ltd

    Antimigraine

    phase 1 other active

    1 trial

  39. UP0122

    Lacuna Pharma Pty Ltd

    Hidradenitis suppurativa, Axial spondyloarthritis, Moderate to Severe Plaque Psoriasis, Psoriatic arthritis

    phase 1 small molecule active

    1 trial

  40. UP0124

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 other active

    1 trial

  41. UPADA-01-24

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis

    phase 1 other active

    1 trial

  42. UPADA-02-24

    Lacuna Pharma Pty Ltd

    Axial spondyloarthritis, Crohn’s disease, Ulcerative colitis, Atopic dermatitis, Rheumatoid arthritis, Psoriatic arthritis

    phase 1 other active

    1 trial

  43. UPADA-03-24

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis

    phase 1 other active

    1 trial

  44. UR001

    Lacuna Pharma Pty Ltd

    Non-muscle Invasive Bladder Cancer

    phase 1 other active

    1 trial

  45. VAR2-2024-CS01

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  46. VP-C21-014

    Lacuna Pharma Pty Ltd

    Idiopahtic pulmonary fibrosis

    phase 1 other active

    1 trial

  47. VP-C21-016

    Lacuna Pharma Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 1 other active

    1 trial

  48. VP-VTR-297-1101

    Lacuna Pharma Pty Ltd

    relapsed/refractory hematologic malignancies

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.